191 related articles for article (PubMed ID: 18256546)
21. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
23. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length.
Lai Z; Auger KR; Manubay CM; Copeland RA
Arch Biochem Biophys; 2000 Sep; 381(2):278-84. PubMed ID: 11032416
[TBL] [Abstract][Full Text] [Related]
24. Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics.
Verkhivker GM
PLoS One; 2012; 7(7):e40897. PubMed ID: 22815859
[TBL] [Abstract][Full Text] [Related]
25. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
27. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
Kannan S; Partridge AW; Lane DP; Verma CS
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
[TBL] [Abstract][Full Text] [Related]
28. Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations.
Yadahalli S; Li J; Lane DP; Gosavi S; Verma CS
Sci Rep; 2017 Nov; 7(1):15600. PubMed ID: 29142290
[TBL] [Abstract][Full Text] [Related]
29. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
[TBL] [Abstract][Full Text] [Related]
30. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
31. The C terminus of p53 binds the N-terminal domain of MDM2.
Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
[TBL] [Abstract][Full Text] [Related]
32. Targeting protein-protein interactions: lessons from p53/MDM2.
Murray JK; Gellman SH
Biopolymers; 2007; 88(5):657-86. PubMed ID: 17427181
[TBL] [Abstract][Full Text] [Related]
33. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
[TBL] [Abstract][Full Text] [Related]
34. Binding Ensembles of
Lang L; Perez A
Molecules; 2021 Jan; 26(1):. PubMed ID: 33401765
[TBL] [Abstract][Full Text] [Related]
35. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100.
Dastidar SG; Lane DP; Verma CS
BMC Bioinformatics; 2009 Dec; 10 Suppl 15(Suppl 15):S6. PubMed ID: 19958516
[TBL] [Abstract][Full Text] [Related]
36. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
37. Direct observations of conformational distributions of intrinsically disordered p53 peptides using UV Raman and explicit solvent simulations.
Xiong K; Zwier MC; Myshakina NS; Burger VM; Asher SA; Chong LT
J Phys Chem A; 2011 Sep; 115(34):9520-7. PubMed ID: 21528875
[TBL] [Abstract][Full Text] [Related]
38. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
39. Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions.
Ricardo MG; Ali AM; Plewka J; Surmiak E; Labuzek B; Neochoritis CG; Atmaj J; Skalniak L; Zhang R; Holak TA; Groves M; Rivera DG; Dömling A
Angew Chem Int Ed Engl; 2020 Mar; 59(13):5235-5241. PubMed ID: 31944488
[TBL] [Abstract][Full Text] [Related]
40. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
